Qiagen (NYSE:QGEN) Receives Average Recommendation of "Hold" from Brokerages

Qiagen (NYSE:QGEN - Get Free Report) has been given an average rating of "Hold" by the ten ratings firms that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $48.42.

QGEN has been the subject of a number of recent analyst reports. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Robert W. Baird upped their price target on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. UBS Group lowered their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. StockNews.com upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Friday, May 9th. Finally, Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th.

Qiagen Price Performance

Shares of Qiagen stock opened at $42.08 on Wednesday. Qiagen has a 52-week low of $37.63 and a 52-week high of $49.30. The stock has a market capitalization of $9.35 billion, a price-to-earnings ratio of 117.17, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The company has a fifty day moving average of $40.80 and a 200-day moving average of $41.78. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. During the same period in the prior year, the business posted $0.44 EPS. The firm's revenue was up 5.2% compared to the same quarter last year. Equities research analysts expect that Qiagen will post 2.26 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC raised its holdings in Qiagen by 102.4% in the 1st quarter. Neuberger Berman Group LLC now owns 19,352 shares of the company's stock worth $767,000 after purchasing an additional 9,791 shares in the last quarter. Prudential PLC raised its holdings in Qiagen by 132.5% in the 1st quarter. Prudential PLC now owns 47,166 shares of the company's stock worth $1,862,000 after purchasing an additional 26,880 shares in the last quarter. Public Sector Pension Investment Board raised its holdings in Qiagen by 5.2% in the 1st quarter. Public Sector Pension Investment Board now owns 113,046 shares of the company's stock worth $4,478,000 after purchasing an additional 5,593 shares in the last quarter. Nuveen LLC bought a new position in Qiagen in the 1st quarter worth $44,078,000. Finally, Invesco Ltd. raised its holdings in Qiagen by 13.5% in the 1st quarter. Invesco Ltd. now owns 449,638 shares of the company's stock worth $18,053,000 after purchasing an additional 53,383 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.